vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and PROSPERITY BANCSHARES INC (PB). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $367.6M, roughly 1.9× PROSPERITY BANCSHARES INC). PROSPERITY BANCSHARES INC runs the higher net margin — 31.6% vs 19.1%, a 12.6% gap on every dollar of revenue. Over the past eight quarters, PROSPERITY BANCSHARES INC's revenue compounded faster (19.2% CAGR vs 17.7%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...
MEDP vs PB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $367.6M |
| Net Profit | $135.1M | $116.3M |
| Gross Margin | — | — |
| Operating Margin | 21.6% | — |
| Net Margin | 19.1% | 31.6% |
| Revenue YoY | 32.0% | — |
| Net Profit YoY | 15.5% | -10.7% |
| EPS (diluted) | $4.65 | $1.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $367.6M | ||
| Q4 25 | $708.5M | $275.0M | ||
| Q3 25 | $659.9M | $273.4M | ||
| Q2 25 | $603.3M | $267.7M | ||
| Q1 25 | $558.6M | $265.4M | ||
| Q4 24 | $536.6M | $267.8M | ||
| Q3 24 | $533.3M | $261.7M | ||
| Q2 24 | $528.1M | $258.8M |
| Q1 26 | — | $116.3M | ||
| Q4 25 | $135.1M | $139.9M | ||
| Q3 25 | $111.1M | $137.6M | ||
| Q2 25 | $90.3M | $135.2M | ||
| Q1 25 | $114.6M | $130.2M | ||
| Q4 24 | $117.0M | $130.1M | ||
| Q3 24 | $96.4M | $127.3M | ||
| Q2 24 | $88.4M | $111.6M |
| Q1 26 | — | — | ||
| Q4 25 | 21.6% | 65.1% | ||
| Q3 25 | 21.5% | 64.4% | ||
| Q2 25 | 20.9% | 64.3% | ||
| Q1 25 | 20.3% | 62.7% | ||
| Q4 24 | 23.4% | 62.0% | ||
| Q3 24 | 21.1% | 62.1% | ||
| Q2 24 | 19.9% | 55.2% |
| Q1 26 | — | 31.6% | ||
| Q4 25 | 19.1% | 50.9% | ||
| Q3 25 | 16.8% | 50.3% | ||
| Q2 25 | 15.0% | 50.5% | ||
| Q1 25 | 20.5% | 49.1% | ||
| Q4 24 | 21.8% | 48.6% | ||
| Q3 24 | 18.1% | 48.6% | ||
| Q2 24 | 16.7% | 43.1% |
| Q1 26 | — | $1.16 | ||
| Q4 25 | $4.65 | $1.48 | ||
| Q3 25 | $3.86 | $1.45 | ||
| Q2 25 | $3.10 | $1.42 | ||
| Q1 25 | $3.67 | $1.37 | ||
| Q4 24 | $3.67 | $1.36 | ||
| Q3 24 | $3.01 | $1.34 | ||
| Q2 24 | $2.75 | $1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $8.2B |
| Total Assets | $2.0B | $43.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $497.0M | — | ||
| Q3 25 | $285.4M | — | ||
| Q2 25 | $46.3M | — | ||
| Q1 25 | $441.4M | — | ||
| Q4 24 | $669.4M | — | ||
| Q3 24 | $656.9M | — | ||
| Q2 24 | $510.9M | — |
| Q1 26 | — | $8.2B | ||
| Q4 25 | $459.1M | $7.6B | ||
| Q3 25 | $293.6M | $7.7B | ||
| Q2 25 | $172.4M | $7.6B | ||
| Q1 25 | $593.6M | $7.5B | ||
| Q4 24 | $825.5M | $7.4B | ||
| Q3 24 | $881.4M | $7.4B | ||
| Q2 24 | $763.6M | $7.3B |
| Q1 26 | — | $43.6B | ||
| Q4 25 | $2.0B | $38.5B | ||
| Q3 25 | $1.8B | $38.3B | ||
| Q2 25 | $1.6B | $38.4B | ||
| Q1 25 | $1.9B | $38.8B | ||
| Q4 24 | $2.1B | $39.6B | ||
| Q3 24 | $2.1B | $40.1B | ||
| Q2 24 | $1.9B | $39.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | — |
| Free Cash FlowOCF − Capex | $188.1M | — |
| FCF MarginFCF / Revenue | 26.6% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $192.7M | $78.3M | ||
| Q3 25 | $246.2M | $194.8M | ||
| Q2 25 | $148.5M | $98.2M | ||
| Q1 25 | $125.8M | $178.2M | ||
| Q4 24 | $190.7M | $-205.8M | ||
| Q3 24 | $149.1M | $274.6M | ||
| Q2 24 | $116.4M | $216.5M |
| Q1 26 | — | — | ||
| Q4 25 | $188.1M | $68.5M | ||
| Q3 25 | $235.5M | $185.7M | ||
| Q2 25 | $142.4M | $91.8M | ||
| Q1 25 | $115.8M | $171.1M | ||
| Q4 24 | $183.0M | $-210.7M | ||
| Q3 24 | $138.5M | $270.2M | ||
| Q2 24 | $103.5M | $211.8M |
| Q1 26 | — | — | ||
| Q4 25 | 26.6% | 24.9% | ||
| Q3 25 | 35.7% | 67.9% | ||
| Q2 25 | 23.6% | 34.3% | ||
| Q1 25 | 20.7% | 64.5% | ||
| Q4 24 | 34.1% | -78.7% | ||
| Q3 24 | 26.0% | 103.3% | ||
| Q2 24 | 19.6% | 81.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 3.6% | ||
| Q3 25 | 1.6% | 3.3% | ||
| Q2 25 | 1.0% | 2.4% | ||
| Q1 25 | 1.8% | 2.7% | ||
| Q4 24 | 1.4% | 1.8% | ||
| Q3 24 | 2.0% | 1.7% | ||
| Q2 24 | 2.4% | 1.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 0.56× | ||
| Q3 25 | 2.22× | 1.42× | ||
| Q2 25 | 1.65× | 0.73× | ||
| Q1 25 | 1.10× | 1.37× | ||
| Q4 24 | 1.63× | -1.58× | ||
| Q3 24 | 1.55× | 2.16× | ||
| Q2 24 | 1.32× | 1.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
